Literature DB >> 21266505

Hormone-related risk factors and postmenopausal breast cancer among nulliparous versus parous women: An aggregated study.

Sara J Schonfeld1, Ruth M Pfeiffer, James V Lacey, Amy Berrington de González, Michele M Doody, Robert T Greenlee, Yikyung Park, Catherine Schairer, Arthur Schatzkin, Alice J Sigurdson, Patricia Hartge, Kala Visvanathan.   

Abstract

Nulliparity is an established breast cancer risk factor, particularly when compared with parity at young ages. The authors aggregated data from 4 US prospective studies (1979-2006) including 32,641 nulliparous (1,612 breast cancers) and 204,270 parous (8,180 breast cancers) women to examine the hypothesis that nulliparity may increase susceptibility to established postmenopausal breast cancer risk factors. The aggregated hazard ratio for nulliparous versus all parous women = 1.27 (95% confidence interval: 1.21, 1.34), and that for nulliparous versus women <25 years of age at first birth = 1.38 (95% confidence interval: 1.30, 1.46). Among nulliparous women, the hazard ratios for current menopausal hormone therapy use (vs. never use), body mass index ≥30 kg/m(2) (vs. <25 kg/m(2)), and weekly consumption of ≥7 alcoholic drinks (vs. none) ranged from 1.3 to 1.6. The hazard ratios did not differ by parity. In a model including all women, the joint association for each of these factors and nulliparity combined compared with first birth before age 25 years was an approximately 2-fold increased breast cancer risk. Although the baseline risk is higher for nulliparous women compared with parous women, these results suggest that the associations between hormone-related factors and breast cancer do not differ by parity.

Entities:  

Mesh:

Year:  2011        PMID: 21266505      PMCID: PMC3105439          DOI: 10.1093/aje/kwq404

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  38 in total

1.  Age-related lobular involution and risk of breast cancer.

Authors:  Tia R Milanese; Lynn C Hartmann; Thomas A Sellers; Marlene H Frost; Robert A Vierkant; Shaun D Maloney; V Shane Pankratz; Amy C Degnim; Celine M Vachon; Carol A Reynolds; Romayne A Thompson; L Joseph Melton; Ellen L Goode; Daniel W Visscher
Journal:  J Natl Cancer Inst       Date:  2006-11-15       Impact factor: 13.506

2.  Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis.

Authors:  Gillian K Reeves; Valerie Beral; Jane Green; Toral Gathani; Diana Bull
Journal:  Lancet Oncol       Date:  2006-11       Impact factor: 41.316

3.  Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort.

Authors:  Louise A Brinton; Douglas Richesson; Michael F Leitzmann; Gretchen L Gierach; Arthur Schatzkin; Traci Mouw; Albert R Hollenbeck; James V Lacey
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11       Impact factor: 4.254

4.  National use of postmenopausal hormone therapy: annual trends and response to recent evidence.

Authors:  Adam L Hersh; Marcia L Stefanick; Randall S Stafford
Journal:  JAMA       Date:  2004-01-07       Impact factor: 56.272

5.  Full-term pregnancy induces a specific genomic signature in the human breast.

Authors:  Jose Russo; Gabriela A Balogh; Irma H Russo
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-01       Impact factor: 4.254

Review 6.  The protective role of pregnancy in breast cancer.

Authors:  Jose Russo; Raquel Moral; Gabriela A Balogh; Daniel Mailo; Irma H Russo
Journal:  Breast Cancer Res       Date:  2005-04-07       Impact factor: 6.466

7.  Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies.

Authors:  Huiyan Ma; Leslie Bernstein; Malcolm C Pike; Giske Ursin
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

Review 8.  Pregnancy and the risk of breast cancer.

Authors:  Kara Britt; Alan Ashworth; Matthew Smalley
Journal:  Endocr Relat Cancer       Date:  2007-12       Impact factor: 5.678

9.  Prospective study of physical activity and risk of postmenopausal breast cancer.

Authors:  Michael F Leitzmann; Steven C Moore; Tricia M Peters; James V Lacey; Arthur Schatzkin; Catherine Schairer; Louise A Brinton; Demetrius Albanes
Journal:  Breast Cancer Res       Date:  2008-10-31       Impact factor: 6.466

10.  Lifetime cumulative number of menstrual cycles and serum sex hormone levels in postmenopausal women.

Authors:  Mariana Chavez-MacGregor; Carla H van Gils; Yvonne T van der Schouw; Evelyn Monninkhof; Paulus A H van Noord; Petra H M Peeters
Journal:  Breast Cancer Res Treat       Date:  2007-05-22       Impact factor: 4.872

View more
  14 in total

1.  Targeted DNA Methylation Screen in the Mouse Mammary Genome Reveals a Parity-Induced Hypermethylation of Igf1r That Persists Long after Parturition.

Authors:  Tiffany A Katz; Serena G Liao; Vincent J Palmieri; Robert K Dearth; Thushangi N Pathiraja; Zhiguang Huo; Patricia Shaw; Sarah Small; Nancy E Davidson; David G Peters; George C Tseng; Steffi Oesterreich; Adrian V Lee
Journal:  Cancer Prev Res (Phila)       Date:  2015-08-19

2.  Breast cancer in Wales: time trends and geographical distribution.

Authors:  Ganiy Opeyemi Abdulrahman
Journal:  Gland Surg       Date:  2014-11

3.  An aggregated analysis of hormonal factors and endometrial cancer risk by parity.

Authors:  Sara J Schonfeld; Patricia Hartge; Ruth M Pfeiffer; D Michal Freedman; Robert T Greenlee; Martha S Linet; Yikyung Park; Catherine Schairer; Kala Visvanathan; James V Lacey
Journal:  Cancer       Date:  2012-12-20       Impact factor: 6.860

Review 4.  Relationships between Breast Feeding and Breast Cancer Subtypes: Lessons Learned from Studies in Humans and in Mice.

Authors:  Christine B Ambrosone; Michael J Higgins
Journal:  Cancer Res       Date:  2020-08-14       Impact factor: 12.701

5.  Collagen architecture in pregnancy-induced protection from breast cancer.

Authors:  Ori Maller; Kirk C Hansen; Traci R Lyons; Irene Acerbi; Valerie M Weaver; Rytis Prekeris; Aik-Choon Tan; Pepper Schedin
Journal:  J Cell Sci       Date:  2013-07-10       Impact factor: 5.285

6.  Cancers in Australia in 2010 attributable to total breastfeeding durations of 12 months or less by parous women.

Authors:  Susan J Jordan; Louise F Wilson; Christina M Nagle; Adele C Green; Catherine M Olsen; Christopher J Bain; Nirmala Pandeya; David C Whiteman; Penelope M Webb
Journal:  Aust N Z J Public Health       Date:  2015-10       Impact factor: 2.939

7.  Hormonal risk factors and invasive epithelial ovarian cancer risk by parity.

Authors:  C Bodelon; N Wentzensen; S J Schonfeld; K Visvanathan; P Hartge; Y Park; R M Pfeiffer
Journal:  Br J Cancer       Date:  2013-07-02       Impact factor: 7.640

Review 8.  Potential Mechanisms underlying the Protective Effect of Pregnancy against Breast Cancer: A Focus on the IGF Pathway.

Authors:  Tiffany A Katz
Journal:  Front Oncol       Date:  2016-10-26       Impact factor: 6.244

9.  Women with familial risk for breast cancer have an increased frequency of aldehyde dehydrogenase expressing cells in breast ductules.

Authors:  Björn L Isfoss; Bo Holmqvist; Helena Jernström; Per Alm; Håkan Olsson
Journal:  BMC Clin Pathol       Date:  2013-11-04

10.  NZ51, a ring-expanded nucleoside analog, inhibits motility and viability of breast cancer cells by targeting the RNA helicase DDX3.

Authors:  Min Xie; Farhad Vesuna; Mahendran Botlagunta; Guus Martinus Bol; Ashley Irving; Yehudit Bergman; Ramachandra S Hosmane; Yoshinori Kato; Paul T Winnard; Venu Raman
Journal:  Oncotarget       Date:  2015-10-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.